A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER.

Trial Profile

A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2013

At a glance

  • Drugs Radretumab (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 29 Apr 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 16 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top